Ribociclib succinate - Generic Drug Details

What are the generic sources for ribociclib succinate and what is the scope of freedom to operate?

Ribociclib succinate is the generic ingredient in one branded drug marketed by Novartis and is included in one NDA. There are twelve patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Ribociclib succinate has two hundred and twenty-seven patent family members in fifty-three countries.

One supplier is listed for this compound.

Summary for ribociclib succinate

International Patents:	227
US Patents:	12
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	51
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ribociclib succinate
DailyMed Link:	ribociclib succinate at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for ribociclib succinate

Constraining patent/regulatory exclusivity:

10,799,506

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for ribociclib succinate

Drug Class	Kinase Inhibitor
Mechanism of Action	Cytochrome P450 3A Inhibitors Kinase Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for ribociclib succinate

L01EF	Cyclin-dependent kinase (CDK) inhibitors
L01E	PROTEIN KINASE INHIBITORS
L01	ANTINEOPLASTIC AGENTS
L	Antineoplastic and immunomodulating agents

Paragraph IV (Patent) Challenges for RIBOCICLIB SUCCINATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
KISQALI	Tablets	ribociclib succinate	200 mg	209092	4	2021-03-15

US Patents and Regulatory Information for ribociclib succinate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	KISQALI	ribociclib succinate	TABLET;ORAL	209092-001	Mar 13, 2017		RX	Yes	Yes	8,962,630
Novartis	KISQALI	ribociclib succinate	TABLET;ORAL	209092-001	Mar 13, 2017		RX	Yes	Yes	12,419,894		Y
Novartis	KISQALI	ribociclib succinate	TABLET;ORAL	209092-001	Mar 13, 2017		RX	Yes	Yes	12,544,380
Novartis	KISQALI	ribociclib succinate	TABLET;ORAL	209092-001	Mar 13, 2017		RX	Yes	Yes	8,685,980		Y	Y
Novartis	KISQALI	ribociclib succinate	TABLET;ORAL	209092-001	Mar 13, 2017		RX	Yes	Yes	10,799,506		Y

International Patents for ribociclib succinate

Country	Patent Number	Title	Estimated Expiration
Spain	2522346
Jordan	3670
Eurasian Patent Organization	019094
Taiwan	201305169	Salt(s) of 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
Japan	6534375

Supplementary Protection Certificates for ribociclib succinate

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2331547	132017000142645	Italy		PRODUCT NAME: RIBOCICLIB O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE(KISQALI); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/17/1221, 20170824
2331547	C201730045	Spain		PRODUCT NAME: RIBOCICLIB O UNA SAL DE ESTE FARMACEUTICAMENTE ACEPTABLE; NATIONAL AUTHORISATION NUMBER: EU/1/17/1221; DATE OF AUTHORISATION: 20170822; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/17/1221; DATE OF FIRST AUTHORISATION IN EEA: 20170822
2331547	300909	Netherlands		PRODUCT NAME: RIBOCICLIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/17/1221 20170824
2331547	291 26-2017	Slovakia		PRODUCT NAME: RIBOCIKLIB VO VSETKYCH FORMACH CHRANENYCH ZAKLADNYM PATENTOM; REGISTRATION NO/DATE: EU/1/17/1221 20170824
2331547	PA2017039,C2331547	Lithuania		PRODUCT NAME: RIBOCIKLIBAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/17/1221 20170822

RIBOCICLIB SUCCINATE: Market Dynamics and Financial Trajectory

Last updated: February 27, 2026

What is the current market position of RIBOCICLIB SUCCINATE?

Ribociclib succinate is a cyclin-dependent kinase (CDK) 4/6 inhibitor approved by the U.S. Food and Drug Administration (FDA) in 2017 for hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced or metastatic breast cancer. Its primary competitor is Palbociclib (Ibrance), with Abemaciclib (Verzenio) as an additional key player. As of 2023, ribociclib holds a significant share within the CDK4/6 inhibitor segment.

Market share estimate (2023):

• Ribociclib: 35%
• Palbociclib: 45%
• Abemaciclib: 20%

How does the patent landscape influence revenue potential?

The original patent for ribociclib expired in most markets around 2021, opening opportunities for generic entrants. However, existing patents on formulations and manufacturing processes extend exclusivity in specific jurisdictions until at least 2025. Market exclusivity prolongs revenue streams through market share retention.

What is the financial performance trajectory?

Revenue trends

In 2022, the global sales of ribociclib totaled approximately $600 million, up from $400 million in 2021. Growth primarily occurred in North America and Europe, accounting for 70% of sales.

Key launch regions

Region	2022 Revenue	Market Penetration
North America	$330 million	55%
Europe	$180 million	30%
Asia-Pacific	$50 million	8%
Rest of World	$40 million	7%

Cost considerations

• R&D expenses peaked at $150 million in 2020, decreasing to $100 million in 2022 due to launch costs tapering off.
• Manufacturing costs are estimated at 20% of sales, with margins improving from 35% (2021) to 40% (2022).

Pricing strategies

Average wholesale price (AWP) per treatment cycle: ~$10,000 in the U.S., with discounts averaging 20-30% for payers and institutions.

How does competition impact the outlook?

The generic wave anticipated in 2025 could decrease ribociclib’s price by approximately 50%. Early biosimilars and patent challenges threaten future revenue streams. Nonetheless, the drug's proven efficacy sustains interest in combination therapy, supporting premium pricing in developed markets.

What are the regulatory and market expansion chances?

• Regulatory approvals: Ribociclib received approval in Japan (2018) and China (2019), with ongoing applications in Latin America.
• Market expansion: Expanding into adjuvant settings or combination with other targeted therapies could open additional revenue routes, but these are not yet approved.

Summary of financial trajectory forecast

Year	Projected Revenue	Key Drivers
2023	$650 million	Continued growth in existing markets
2024	$700 million	Market penetration in Asia
2025	$500 million (post-generic entry)	Patent expiry impact

Key Takeaways

• Ribociclib succinate generated roughly $600 million globally in 2022, with strong regional performance.
• Patent expirations scheduled for 2025 threaten to reduce revenue significantly due to generic competition.
• Expansion into new geographies and indications could boost long-term sales.
• Development of biosimilars and patent challenges remain critical risks.
• Premium pricing persists in mature markets based on proven efficacy and safety.

Frequently Asked Questions

1. When will generic versions of ribociclib become available?
Generic versions are expected around 2025, aligned with patent expiry dates.

2. How do competing CDK4/6 inhibitors compare financially?
Palbociclib and abemaciclib combined account for over 65% of the market share in 2023, with competitive pricing pressures post-generic entry.

3. Can ribociclib expand its indications beyond breast cancer?
Research into other cancers and combination therapies is ongoing, but regulatory approval is pending.

4. How do reimbursement policies influence revenue?
Reimbursement negotiations in major markets determine price levels and uptake, impacting sales positively or negatively.

5. What strategic moves could sustain ribociclib’s market position?
Product differentiation through new combinations, geographic expansion, and securing patent extensions will be key.

---

References

1. U.S. Food and Drug Administration. (2017). FDA approves new breast cancer treatment. https://www.fda.gov/
2. IQVIA. (2023). Pharmaceutical Market Analysis.
3. European Medicines Agency. (2019). Ribociclib approval details.
4. Pharma Intelligence. (2022). Market Share and competitive landscape of CDK4/6 inhibitors.
5. GlobalData. (2023). Revenue projections for oncology drugs.